Acorda Therapeutics Company Profile (NASDAQ:ACOR)

About Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ACOR
  • CUSIP: 00484M10
  • Web:
  • Market Cap: $937.85 million
  • Outstanding Shares: 46,758,000
Average Prices:
  • 50 Day Moving Avg: $18.37
  • 200 Day Moving Avg: $20.23
  • 52 Week Range: $13.60 - $33.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -56.53
  • P/E Growth: 0.35
Sales & Book Value:
  • Annual Revenue: $523.08 million
  • Price / Sales: 1.82
  • Book Value: $14.46 per share
  • Price / Book: 1.41
  • EBIDTA: $20.62 million
  • Net Margins: -10.13%
  • Return on Equity: -5.94%
  • Return on Assets: -3.00%
  • Debt-to-Equity Ratio: 0.48%
  • Current Ratio: 2.08%
  • Quick Ratio: 1.69%
  • Average Volume: 875,300 shs.
  • Beta: 1.64
  • Short Ratio: 7.51

Frequently Asked Questions for Acorda Therapeutics (NASDAQ:ACOR)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) issued its quarterly earnings results on Thursday, April, 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.08. The firm earned $119.39 million during the quarter, compared to the consensus estimate of $127.34 million. Acorda Therapeutics had a negative return on equity of 5.94% and a negative net margin of 10.13%. The company's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company posted $0.28 EPS. View Acorda Therapeutics' Earnings History.

When will Acorda Therapeutics make its next earnings announcement?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Acorda Therapeutics.

Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?

9 brokers have issued twelve-month price targets for Acorda Therapeutics' stock. Their predictions range from $19.00 to $35.00. On average, they expect Acorda Therapeutics' stock price to reach $24.67 in the next year. View Analyst Ratings for Acorda Therapeutics.

What are analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

  • 1. According to Zacks Investment Research, "Acorda’s key multiple sclerosis drug Ampyra is facing several patent challenges. Recently a district court invalidated four patents of, Ampyra, thereby making way for generic versions of the drug. Sales Ampyra also declined sequentially in the quarter. The company’s share price underperformed the industry so far this year. With Ampyra facing patent issues, focus has shifted to the company’s late stage parkinson’s candidates Inbrija (formerly known as CVT-301) and tozadenant. However, the company recently submitted regulatory applications for Inbrija in the U.S. and plans to file for the same in the EU by the end of 2017. Meanwhile, Acorda is working on expanding its pipeline by entering into deals and pursuing acquisitions. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/19/2017)
  • 2. Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:

  • Ron Cohen M.D., President,Chief Executive Officer, Director
  • David Lawrence, Chief Business Operations, Principal Accounting Officer
  • Andrew R. Blight Ph.D., Chief Scientific Officer
  • Jane Wasman J.D., President - International, General Counsel, Corporate Secretary
  • Burkhard Blank M.D., Chief Medical Officer
  • Andrew Hindman, Chief Business Development Officer
  • Lauren M. Sabella, Chief Commercial Officer
  • Catherine D. Strader, Director
  • Barry E. Greene, Independent Director
  • Peder K. Jensen M.D., Independent Director

Who owns Acorda Therapeutics stock?

Acorda Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Malaga Cove Capital LLC (0.12%), Whittier Trust Co. (0.08%), Louisiana State Employees Retirement System (0.04%), Aperio Group LLC (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Andrew Blight, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Michael W Rogers, Richard P Batycky, Ron Cohen and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?

Acorda Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Malaga Cove Capital LLC, State of Alaska Department of Revenue, Whittier Trust Co., Aperio Group LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy Acorda Therapeutics stock?

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of Acorda Therapeutics stock can currently be purchased for approximately $20.35.

MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $24.67 (21.21% upside)

Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Jefferies Group LLCInitiated CoverageHold -> Hold$22.00MediumView Rating Details
6/6/2017J P Morgan Chase & CoSet Price TargetHold$24.00LowView Rating Details
6/7/2017Cowen and CompanyReiterated RatingOutperform$35.00LowView Rating Details
4/3/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$22.00HighView Rating Details
4/3/2017Janney Montgomery ScottDowngradeBuy -> Neutral$38.00 -> $19.00HighView Rating Details
3/30/2017Stifel NicolausReiterated RatingBuy$30.00HighView Rating Details
2/15/2017Cantor FitzgeraldReiterated RatingNeutral -> PositiveN/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00N/AView Rating Details
11/23/2016Leerink SwannReiterated RatingMarket PerformN/AView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
7/31/2015Canaccord GenuityReiterated RatingHold$32.00N/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Acorda Therapeutics (NASDAQ:ACOR)
Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Earnings History by Quarter for Acorda Therapeutics (NASDAQ ACOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017$0.49N/AView Earnings Details
4/27/2017Q1 2017($0.16)($0.08)$127.34 million$119.39 millionViewN/AView Earnings Details
2/14/2017Q416($0.18)$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215($0.01)$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.15$0.33$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.04$0.34$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.14$0.24$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.04$0.08$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.03)$0.26$0.12
Q3 20172$0.21$0.56$0.39
Q4 20172$0.32$0.76$0.54
(Data provided by Zacks Investment Research)


Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Acorda Therapeutics (NASDAQ:ACOR)
Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017Ron CohenInsiderBuy20,000$16.95$339,000.00View SEC Filing  
5/15/2017Andrew A HindmanInsiderSell7,704$15.75$121,338.00View SEC Filing  
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.90View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.00View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Acorda Therapeutics (NASDAQ:ACOR)
Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
DateHeadline logoAcorda Therapeutics, Inc. (ACOR) to Release Quarterly Earnings on Wednesday - July 19 at 8:15 AM logoAcorda Second Quarter 2017 Update Webcast/Conference Call Scheduled for July 27, 2017 - Business Wire (press release) - July 13 at 8:55 PM logoAcorda Second Quarter 2017 Update Webcast/Conference Call Scheduled for July 27, 2017 - July 13 at 3:51 PM logoETFs with exposure to Acorda Therapeutics, Inc. : July 13, 2017 - July 13 at 3:51 PM logoAcorda Therapeutics, Inc. (NASDAQ:ACOR) Expected to Post Q2 2017 Earnings of $0.26 Per Share - July 13 at 9:34 AM logoAcorda's Pipeline Has Potential - Seeking Alpha - July 12 at 3:48 PM logoJefferies Group LLC Begins Coverage on Acorda Therapeutics, Inc. (NASDAQ:ACOR) - July 10 at 5:26 PM logoGlobal Pain Drug Development Pipeline Review Report 2017 Featuring 170+ Leading Pharma Companies - July 10 at 3:29 PM logoBRIEF-Christopher James reports 5.9 pct passive stake in Acorda Therapeutics ... - July 8 at 8:15 AM logoAcorda Therapeutics Inc (ACOR) Stock Rating Upgraded by BidaskClub - July 7 at 5:06 PM logoAcorda Therapeutics, Inc. (NASDAQ:ACOR) Given Average Rating of "Buy" by Analysts - July 4 at 5:20 PM logoMultiple Sclerosis Drugs and Therapeutic Pipeline Review H1 2017 Research Available at RnR Market Research - July 4 at 4:29 PM logoAcorda Files NDA for Parkinson's Disease Candidate Inbrija - Nasdaq - June 30 at 3:34 PM logoAcorda Files NDA for Parkinson's Disease Candidate Inbrija - June 30 at 3:34 PM logoAcorda Therapeutics, Inc. (ACOR) Expected to Post Quarterly Sales of $139.89 Million - June 30 at 2:06 PM logoAcorda Therapeutics (ACOR) Submits NDA for INBRIJATM - - June 30 at 1:44 AM logoAcorda Therapeutics (ACOR) Submits NDA for INBRIJATM - June 29 at 8:42 PM logoBRIEF-Acorda submits new drug application to U.S. Food And Drug Administration - June 29 at 8:42 PM logoAcorda Submits New Drug Application to U.S. Food and Drug Administration for INBRIJATM (CVT-301, Levodopa Inhalation Powder) - June 29 at 8:42 PM logoZacks: Brokerages Expect Acorda Therapeutics, Inc. (ACOR) to Post $0.12 EPS - June 28 at 12:26 PM logoETFs with exposure to Acorda Therapeutics, Inc. : June 26, 2017 - June 26 at 3:44 PM logoBiotech Insider Just Loaded Up $234 Million Worth the Stock - June 21 at 3:40 PM logoRon Cohen Buys 20,000 Shares of Acorda Therapeutics, Inc. (ACOR) Stock - June 20 at 4:22 PM logoBiotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe - June 16 at 3:41 PM logoETFs with exposure to Acorda Therapeutics, Inc. : June 15, 2017 - June 15 at 3:35 PM logoAcorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 3:17 PM logoAcorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : June 12, 2017 - June 12 at 3:44 PM logoBRIEF-Acorda Therapeutics, in May 2017, filed planned appeal of decision on 4 invalidated patents with U.S. court of appeals for federal circuit - June 10 at 3:19 PM logoAcorda Therapeutics Inc (ACOR) Given Average Rating of "Buy" by Analysts - June 9 at 7:02 PM logoZacks Initiates on Pulmatrix (NASDAQ:PULM) - June 9 at 3:23 PM logoAcorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : June 9, 2017 - June 9 at 3:23 PM logoAcorda Therapeutics Inc (ACOR) Given a $24.00 Price Target at JPMorgan Chase & Co. - June 7 at 6:40 PM logoAcorda Therapeutics Inc (ACOR) Receives "Outperform" Rating from Cowen and Company - June 7 at 10:26 AM logoAcorda stock surges 10% on positive late-stage Parkinson's results - MarketWatch - June 7 at 1:30 AM logoBRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018 - June 6 at 8:28 PM logoAcorda Therapeutics (ACOR) Presents Parkinson's Disease Drug Overview - Slideshow - June 6 at 8:28 PM logoAcorda Presenting New Tozadenant Data at 2017 MDS Congress - June 6 at 8:28 PM logoAcorda Therapeutics Inc (ACOR): Key Takeaways from CVT-301 Presentation at MDS - June 6 at 8:28 PM logoBRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018​ - Reuters - June 6 at 3:26 PM logoAcorda Presenting New Tozadenant Data at 2017 MDS Congress ... - Business Wire (press release) - June 6 at 3:26 PM logoBiotech Movers: Albany Molecular Shares Soar on Sale to PE Firms - June 6 at 10:16 AM logoAcorda stock surges 10% on positive late-stage Parkinson's results - June 6 at 10:16 AM logoAcorda Therapeutics Inc. (ACOR) Is Climbing On Phase 3 Study Results - June 5 at 11:46 PM logoAcorda Therapeutics +8.5% on positive results in Parkinson's disease drug - Seeking Alpha - June 5 at 6:40 PM logoCVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods in Parkinson’s Disease - June 5 at 6:40 PM logo$139.89 Million in Sales Expected for Acorda Therapeutics Inc (ACOR) This Quarter - June 4 at 9:06 AM logoForm 4 ACORDA THERAPEUTICS INC For: May 31 Filed by: Jensen Peder - June 3 at 1:58 AM logo$0.12 EPS Expected for Acorda Therapeutics Inc (ACOR) This Quarter - June 2 at 10:14 AM logoForm 8-K ACORDA THERAPEUTICS INC For: May 31 - - June 1 at 3:26 PM logoWhy Is Acorda (ACOR) Down 8.4% Since the Last Earnings Report? - June 1 at 3:26 PM



Acorda Therapeutics (ACOR) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff